DBVT · XBRL financial data

DBV Technologies financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DBVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	11,276	5,708	4,844	15,728	4,151	5,636
Research and development	101,607	70,336	75,543	60,223	89,342	116,682
General and administrative	35,081	30,520	24,324	29,500	28,739	32,788
Total operating expenses	170,118	104,323	101,475	92,161	120,740	152,692
Operating income (loss)	(158,842)	(98,614)	(96,631)	(76,432)	(116,589)	(147,056)
Income tax expense (benefit)	(10)	(381)	70	7	55	491
Net income (loss)	(159,555)	(97,809)	(96,274)	(72,726)	113,918	(146,947)
Earnings per share, basic USD per share	—	(1.78)	(1.24)	(0.76)	(1.17)	(1.05)
Earnings per share, diluted USD per share	—	(1.78)	(1.24)	(0.76)	(1.17)	(1.05)
Weighted average shares, basic thousands of shares	—	54,917	77,384	95,121	96,995	139,574
Weighted average shares, diluted thousands of shares	—	54,917	77,384	95,121	96,995	139,574

Fiscal years (DBVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	196,352	77,301	209,194	141,367	32,456	194,167
Inventory	0	—	—	—	—	—
Total current assets	207,375	114,386	223,074	158,915	44,388	212,943
Property and equipment, net	24,792	18,146	15,096	12,623	11,306	10,370
Right-of-use asset	10,104	7,336	2,513	5,247	5,502	4,575
Total assets	272,246	146,723	246,518	182,986	65,658	233,718
Total current liabilities	52,713	31,397	29,521	37,339	31,136	58,025
Lease liability, non-current	10,496	7,147	1,127	4,526	6,297	5,409
Total liabilities	66,754	47,449	52,064	42,799	38,271	64,948
Accumulated deficit	(958,543)	(258,528)	(259,578)	(238,862)	(286,375)	(393,129)
Total stockholders' equity	205,491	99,274	194,453	140,187	27,387	168,770
Total liabilities and equity	272,246	146,723	246,518	182,986	65,658	233,718
Common shares outstanding (cover page) thousands of shares	54,937	55,096	94,137	96,432	136,949	296,042

Fiscal years (DBVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(159,555)	(97,809)	(96,274)	(72,726)	113,918	(146,947)
Stock-based compensation	(1,130)	3,122	5,026	6,019	4,620	5,387
Depreciation and amortization	—	—	—	3,566	2,721	2,987
Net cash from operating activities	(165,607)	(108,242)	(55,666)	(79,653)	(104,474)	(121,181)
Purchases of property and equipment	2,732	910	754	677	2,338	532
Net cash from investing activities	(2,865)	(433)	(100)	(808)	(757)	(1,369)
Proceeds from issuing common stock	150,000	150,000	—	—	—	—
Proceeds from issuing equity	150,449	794	194,471	6,921	634	275,706
Net cash from financing activities	149,548	274	194,120	6,767	587	276,182
Net change in cash	3,097	(119,051)	131,893	(67,827)	(108,913)	161,711

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.